Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
MAGENTA: Phase I Study of Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
Sponsor: Massachusetts General Hospital + Celgene Corporation, Janssen Research and Development LLC
No open prediction endpoints
Endpoints are classified and published by ProgramSignal analysts.
Request endpoint coverageKey Facts
Primary Endpoints (CT.gov)
Recommended Dose
Time frame: Day 1 of treatment through 30 days post last-dose (treatment is until disease progression or withdrawal; estimated to be 1 year from Day 1 of treatment)
Secondary Endpoints
Frequency of adverse events
Frequency of serious adverse events
Frequency of dose-limiting toxicities (DLT)
Eligibility Criteria
Inclusion Criteria: * Participant has given voluntary signed written informed consent before performance of any study-related procedure that is not part of normal medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to their future medical care. * Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (see Appendix). * Age ≥ 18 years * Measurable disease of multiple myeloma as defined by at least one of the following: * Serum monoclonal protein ≥ 0.5 g/dL. Patients with IgD disease and lower amounts of monoclonal protein may be permitted to enroll with PI approval * ≥ 200 mg of monoclonal protein in the urine on 24-hour urine protein electrophoresis * Serum free light chain (FLC) ≥ 100 mg/L (10 mg/dL) and abnormal serum free light chain ratio * Previously treated relapsed and refractory multiple myeloma: * Patients must have received at least three prior lines of therapy; * Prior therapy including an i…
Read full criteria on CT.gov →✦ Analyst Commentary
Expert commentary on why this trial matters and what to watch for.
Request coverage →